Candel therapeutics announces participation in upcoming society for immunotherapy of cancer's (sitc) 36th annual meeting

Needham, mass., oct. 04, 2021 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the company will present novel biomarker data from the ongoing phase 1 clinical trial of can-3110 in recurrent high-grade glioma at the society for immunotherapy of cancer's (sitc) 36th annual meeting taking place november 10-14, 2021 in washington d.c., and virtually.
CADL Ratings Summary
CADL Quant Ranking